Supply Chain Intelligence

Guardant Health, Inc. Supply Chain

GH supply chain intelligence for Guardant Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GH ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

17Suppliers
27Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Guardant Health, Inc. (GH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

48Total relationships
3Distinct source URLs
7High confidence
0.726Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Guardant Health, Inc. Suppliers

TickerNameConfidenceEvidence
CAI Caris Life Sciences, Inc. 72% Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: Reciprocal relationship from CAI graph: R…
CAI Caris Life Sciences, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
EXAS Exact Sciences Corp 72% Reciprocal relationship from EXAS graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
EXAS Exact Sciences Corp 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
FLGT Fulgent Genetics, Inc. 72% Reciprocal relationship from FLGT graph: ry equipment, supplies, and services for our flow cytometry tests and testing services; on Leica Biosystems for an automated digital scanning solution to scal…
GRAL GRAIL, Inc. 72% Reciprocal relationship from GRAL graph: ess tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
MYGN Myriad Genetics, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
NEO NeoGenomics, Inc. 72% Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory tes…
PACB Pacific Biosciences of California, Inc. 72% Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that c…
PACB Pacific Biosciences of California, Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
PSNL Personalis, Inc. 72% Reciprocal relationship from PSNL graph: Reciprocal relationship from GH graph: Reciprocal relationship from PSNL graph: Reciprocal relationship from GH graph: Reciprocal relationship from PSNL graph…
TEM Tempus AI, Inc. 72% Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to t…
TMO Thermo Fisher Scientific Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that co…
VCYT Veracyte, Inc. 72% Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with…
YDES YD Bio Ltd 72% Reciprocal relationship from YDES graph: Reciprocal relationship from GH graph: Reciprocal relationship from YDES graph: Reciprocal relationship from GH graph: Reciprocal relationship from YDES graph…

Guardant Health, Inc. Customers

TickerNameConfidenceEvidence
BIOPHARMACEUTICAL-CUSTOMERS BIOPHARMACEUTICAL-CUSTOMERS 92% Biopharmaceutical customers collaborate with us for analysis of whole blood or plasma samples for multiple applications primarily to support clinical studies, including patient identification, compan…
DOMESTIC-BIOPHARMACEUTICAL-CUSTOMERS DOMESTIC-BIOPHARMACEUTICAL-CUSTOMERS 90% we generate revenue from licensing our digital sequencing technologies to our domestic biopharmaceutical customers and international laboratory partners.
INTERNATIONAL-LABORATORY-PARTNERS INTERNATIONAL-LABORATORY-PARTNERS 90% we generate revenue from licensing our digital sequencing technologies to our domestic biopharmaceutical customers and international laboratory partners.
CAI Caris Life Sciences, Inc. 72% Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018…
CAI Caris Life Sciences, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
EXAS Exact Sciences Corp 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
EXAS Exact Sciences Corp 72% Reciprocal relationship from EXAS graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
MYGN Myriad Genetics, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: Reciprocal relationship from MYGN graph…
NEO NeoGenomics, Inc. 72% Reciprocal relationship from NEO graph: Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: r…
PACB Pacific Biosciences of California, Inc. 72% Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: Reciprocal relationship from PACB graph…
PACB Pacific Biosciences of California, Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
TEM Tempus AI, Inc. 72% tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Caris Life Science, Foundation Medicine, Inc. and Quest Diagnostics, Inc., among …
TEM Tempus AI, Inc. 72% Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Ca…
TMO Thermo Fisher Scientific Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that co…
VCYT Veracyte, Inc. 72% Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with…
ADICON-HOLDINGS-LIMITED ADICON-HOLDINGS-LIMITED 62% lated to the amount that payers reimburse us for any of our tests, we estimate the amount of revenue to be recognized at the time a test is provided and record revenue adjustments if and when the cas…
BIO-REFERENCE-LABORATORIES-INC-LABORATORY-CORPOR BIO-REFERENCE-LABORATORIES-INC-LABORATORY-CORPOR 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…
CALIFORNIA-INC-ULTIMA-GENOMICS-INC-OXFORD-NANOPO CALIFORNIA-INC-ULTIMA-GENOMICS-INC-OXFORD-NANOPO 62% performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could preven…
GRAIL-INC-EXACT-SCIENCES-CORP-FREENOME-HOLDINGS- GRAIL-INC-EXACT-SCIENCES-CORP-FREENOME-HOLDINGS- 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…
ILLUMINA-INC-THERMO-FISHER-SCIENTIFIC-INC ILLUMINA-INC-THERMO-FISHER-SCIENTIFIC-INC 62% performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could preven…
METASIGHT-DIAGNOSTICS-LTD METASIGHT-DIAGNOSTICS-LTD 62% 111,078 107,696 Computer hardware 43,542 41,329 Construction in progress 36,074 41,252 Furniture and fixtures 8,462 8,464 Computer software 2,006 2,006 Property and equipment, gross 355,034 344,816 L…
MYRIAD-GENETICS-INC-CARIS-LIFE-SCIENCE-FOUNDATIO MYRIAD-GENETICS-INC-CARIS-LIFE-SCIENCE-FOUNDATIO 62% tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Caris Life Science, Foundation Medicine, Inc. and Quest Diagnostics, Inc., among …
NATERA-INC-TEMPUS-AI-INC-EXACT-SCIENCES-CORP NATERA-INC-TEMPUS-AI-INC-EXACT-SCIENCES-CORP 62% tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Caris Life Science, Foundation Medicine, Inc. and Quest Diagnostics, Inc., among …
QUEST-DIAGNOSTICS-INC QUEST-DIAGNOSTICS-INC 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…
TWINSTRAND-BIOSCIENCES-INC TWINSTRAND-BIOSCIENCES-INC 62% to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all. At-The-Market Offering …

Guardant Health, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GH-DEBT-9776 Warrants outstanding: 495775 90% xbrl warrant detail from xbrl 2020-12-31.
GH-DEBT Debt stack $1.5B 90% Market cache reports total debt of $1.5B.
GH-DEBT-9777 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Guardant Health, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Guardant Health, Inc..

Guardant Health, Inc. Ownership

HolderNameConfidenceEvidence
GH-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 488 tracked holders.

Guardant Health, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ABT Abbott Laboratories 100.00 2
ATYR aTyr Pharma, Inc. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
CAI Caris Life Sciences, Inc. 100.00 2 ['customer', 'supplier']
BNBX BNB Plus Corp. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
DGX Quest Diagnostics Incorporated 100.00 2
BTAI BioXcel Therapeutics, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 1 ['supplier']
CAPR Capricor Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
RXRX Recursion Pharmaceuticals, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
GRAL GRAIL, Inc. 100.00 1 ['supplier']
BHPLF BHP Group Limited 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Guardant Health, Inc..

Unlock full GH data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
GH
Unlock GH Supply Chain Data
Verified relationships include:
CAICaris Life Sciences, Inc.Supplier72%
CAICaris Life Sciences, Inc.Supplier72%
BIOPHARMACEUTICAL-CUSTOMERSBIOPHARMACEUTICAL-CUSTOMERSCustomer92%
DOMESTIC-BIOPHARMACEUTICAL-CUSTOMERSDOMESTIC-BIOPHARMACEUTICA…Customer90%
+44 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →